Over-prescription of short-acting β ₂ -agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study

SABA over-prescription was common in Latin America, highlighting the need for urgent collaboration between healthcare providers and policymakers to align clinical practices with the latest evidence-based recommendations to address this public health concern.